Lv5
820 积分 2024-03-05 加入
Identification of a dual JAK3/TEC family kinase inhibitor for atopic dermatitis therapy
17天前
已完结
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial
1个月前
已完结
Therapeutic activity of a new KRASG12C inhibitor JMKX001899 in brain metastases: Preclinical models of KRASG12C-mutant non-small cell lung cancer
3个月前
已完结
PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer
4个月前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
4个月前
已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
4个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
4个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
4个月前
已完结
Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial
4个月前
已完结
BiTE: Teaching antibodies to engage T-cells for cancer therapy
5个月前
已关闭
皖公网安备34019202002308
